Borealis-1™: Phase 2 trial of gemcitabine/cisplatin plus apatorsen in advanced bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the international phase 2 Borealis-1™ trial, which evaluated the efficacy and safety of gemcitabine and cisplatin plus apatorsen, a novel antisense oligonucleotide that inhibits Hsp27 production, in patients with advanced bladder cancer.

Year of Production:
Running Time:
Color/Sound:

2015
01:16
Color/Sound

Comments are closed.